Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Published:2023-12 Issue:12 Volume:24 Page:1423-1433
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Niemann Carsten U,Munir Talha,Moreno Carol,Owen Carolyn,Follows George A,Benjamini Ohad,Janssens Ann,Levin Mark-David,Robak Tadeusz,Simkovic Martin,Voloshin Sergey,Vorobyev Vladimir,Yagci Munci,Ysebaert Loic,Qi Keqin,Qi Qianya,Sinet Pierre,Parisi Lori,Srinivasan Srimathi,Schuier Natasha,Baeten Kurt,Howes Angela,Caces Donne Bennett,Kater Arnon P

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia;Gordon;Ther Adv Hematol,2021

2. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia;Barr;Blood Adv,2022

3. Ghia P, Owen C, Barrientos JC, et al. Initiating first-line ibrutinib in patients with chronic lymphocytic leukemia (CLL) improves overall survival outcomes to rates approximating an age-matched population of ≥65 years. 64th Annual American Society of Hematology (ASH) Meeting & Exposition; Dec 10–13, 2022 (poster 1809).

4. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma;Munir;Am J Hematol,2019

5. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial;Shanafelt;Blood,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The GLOW trial in chronic lymphocytic leukaemia;The Lancet Oncology;2024-02

2. The GLOW trial in chronic lymphocytic leukaemia – Authors' reply;The Lancet Oncology;2024-02

3. The GLOW trial in chronic lymphocytic leukaemia;The Lancet Oncology;2024-02

4. Long-term efficacy of ibrutinib–venetoclax for first-line treatment in chronic lymphocytic leukaemia;The Lancet Oncology;2023-12